Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδ T Cells in PD-1 Resistant HCC
NCT06364800Phase 1Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
01
Overview
Phase 1, randomised, open-label trial of allogeneic gamma-delta T cells in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Incidence of Adverse events (AEs) up to 60 weeks, Dose limited toxicity (DLTs) up to 60 weeks and 4 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06364800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364800.